F  Welcome Speech: Dr. Yigong Shi (Tsinghua U.) and Dr. Emilio A. Emini (Pfizer Inc.)

F  9:00 to 12:30 Infection and Immunity against Infectious Diseases (~25min each)

²  9:00-10:30 Chair: Jingren Zhang (Tsinghua U.)

ž   Systematic approaches to study TB infection and development of effective vaccine and therapeutic (Harvard U.) (Eric Rubin)

ž   A high throughput strategy to profile B cell repertoires in emerging infections for development of therapeutic antibodies and protective vaccines (Duke U.) (Larry Liao)

ž   From Neutralizing Antibodies to an Effective HIV-1 Vaccine: Structure-Based Approaches (Vaccine Research Center, NIH, US) (Tongqing Zhou)

²  10:30-10:40 Tea break

²  10:40-12:00 Chair: Li Wu (Tsinghua U.)

ž   Comprehensive analysis of antibody responses during viral infection (TU) (Linqi Zhang)

ž   Immune regulation during chronic HBV infection (Duke U) (Youwen He)

ž   EV71 epidemiology in China (China CDC) (Wenbo Xu)

F  12:30-14:00 Lunch

F  14:00-17:00 Vaccine R&D: Market Needs, Challenges and Trends (~25min each)

²  14:00-15:30Chair: Hai Qi (Tsinghua U.)

ž   Vaccine R&D: New Trends and Novel Adjuvent Technologies (Pfizer) (Nick Jackson)

ž   Pathogenesis and vaccine against Pneumococcal infection (TU) (Jingren Zhang)

ž   Helicobacter pylori and Vaccine (Third Military Medical University (Quan-Ming Zou)

²  15:30-15:40 Tea break

²  15:40-17:00 Chair: Linqi Zhang (Tsinghua U.)

ž   The Critical Path to Proof of Concept Vaccine Efficacy Trials with Envelope-Based HIV Vaccines (Novartis) (Susan W. Barnett )

ž   A promising prime-boost vaccine regimen for AIDS (University of Hong Kong) (Zhiwei Chen)

ž   Strategies to development vaccine under new situation ( National vaccine and Serum Institute ) (Xinliang Shen)

ž   New technologies in vaccine development: ChimeriVax applications (Head of Clinical R&D for sanofi pasteur in Asia)( Alain Bouckenooghe )